Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is an insulin analog presented as an injectable solution for subcutaneous use. It is used to manage blood glucose levels in people with diabetes mellitus type 1 and type 2.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU marketing authorisation and quality standards. The company provides reliable cold‑chain logistics to ensure product integrity during global distribution.

Insulin Aspart is a rapid‑acting insulin analog used in the management of diabetes mellitus.

- Diabetes mellitus type 1: provides rapid post‑prandial glucose reduction to match meal carbohydrate intake. - Diabetes mellitus type 2: offers rapid post‑prandial glucose control as part of basal‑bolus regimens or insulin intensification.

Like other rapid‑acting insulin analogues, Insulin Aspart may be associated with a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: symptoms such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Weight gain: modest increase in body weight over time.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged or unconscious episodes requiring assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Insulin antibody formation: may affect insulin efficacy. - Edema: unexplained swelling of extremities.

When prescribing or using Insulin Aspart, several safety considerations should be observed.

- Dose adjustment: modify dose based on blood glucose monitoring, renal function, and dietary intake. - Hypoglycaemia risk: educate patients on recognizing and treating low blood glucose. - Pregnancy and lactation: assess benefit‑risk ratio; use only if clearly needed. - Concomitant medications: monitor agents that may potentiate hypoglycaemia, such as sulfonylureas. - Driving and machinery: advise caution if experiencing hypoglycaemia symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, altering its glucose‑lowering effect or increasing adverse risk.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use may cause severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection. - Corticosteroids: can increase insulin resistance, necessitating dose escalation.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance insulin sensitivity, requiring dose review. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin effectiveness. - Oral contraceptives: may affect insulin requirements modestly.